Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, pivotal, randomized double-blind, placebo-controlled, safety, tolerability and efficacy study of MSB-01 to treat atopic dermatitis

Next Previous
Search
Trial Profile

A Phase IIb, pivotal, randomized double-blind, placebo-controlled, safety, tolerability and efficacy study of MSB-01 to treat atopic dermatitis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MSB-0221 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors MatriSys Bio

    • Most Recent Events

    • 20 Mar 2019 According to a MatriSys Bioscience media release, the company has successfully completed a pre-IND review with the U.S. Food and Drug Administration (FDA). The FDA provided positive feedback regarding the planned initiation of clinical trials for MSB-01 under a U.S. IND for atopic dermatitis.
    • 11 Jan 2019 New trial record
    • 03 Jan 2019 According to a MatriSys Bioscience media release, the company has submitted a pre-IND (Investigational New Drug) meeting request letter to the U.S. Food and Drug Administration (FDA) to finalize preparations for this company-sponsored trial. This trial is expected to begin in mid-2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top